ArticleTargeted oncology2024

Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.

Keisuke Onoi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.